Heritage Cannabis Holdings Corp TRJTF

July 20th 2017 news release

[Opportunity44]

Propagation material Vancouver, B.C. / TheNewswire / July 20, 2017 UMBRAL ENERGY CORP. (CSE: UMB) ( Umbral or Company ) on behalf of the management of PhyeinMed Inc. (PhyeinMed), a Health Canada late stage applicant under the ACMPR (Access to Cannabis for Medical Purposes Regulations), announces that it has signed an agreement with CanGenX BioTech Inc. (CanGenX) to undertake plant tissue culture as its production basis. CanGenX provides advanced production technologies to the legal medical cannabis industry. PhyeinMed expects that applied science can be used to gain a competitive edge in this newly regulated marketplace. This is done using t issue culture micro-propagation, which can take one plant and multiply it into thousands within a few months. allowing PhyeinMed to take its best performing plants and replicate them to fill their entire production system. The intended result is to create genetically uniform, robust, and disease-free starting plant material, and thereby eliminating traditional propagating methods which are subject to genetic variability, reduced germination and survival rates, and can contain disease. CanGenX facilitates the supply of high volume tissue culture starter plants in house with the purpose of permitting PhyeinMed to produce the safest cannabis possible. Debra Senger, CEO of PhyeinMed states we are excited to move forward with CanGenX as we expect it to deliver us many benefits including uniformity of crop, quicker propagation and a savings of cost and time in production. In this new competitive market, we are aiming to be a quality producer while focusing on optimizing returns in our operations. In addition, CanGenX will consult on the set up a propagation lab facility as well as supplying proprietary strain-specific media to PhyeinMed on demand. Read more at https://www.stockhouse.com/news/press-releases/2017/07/20/start-up-materials-secured-for-production#ROHcQEttJ2J6IgfP.99